The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs.

The fact that lenacapavir will soon be available to patients is a testament to the strength of America's biopharmaceutical ...

A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering have developed a compound that could work as a broad-spectrum drug targeting a range of coronaviruses. Their ...

A new combination drug therapy is showing extraordinary promise in the bout against obesity, helping patients lose an average of 20 percent of their body weight in a major clinical trial.

Preliminary quarterly sales figures for Vykat surpassed Wall Street estimates, but shares fell on concerns the company may ...

Grace Therapeutics’ novel drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, enhanced efficacy, reduced ...

New drugs, such as GLP-1 agonists like semaglutide, have emerged as effective treatments. However, alternatives or complementary treatments could further improve results and reduce side effects.

Leaders of the FDA have published a list of new priorities for the agency. They want to deliver rapidly-approved cures and "unleash AI." Earlier this week, two new leaders of the US Food and Drug ...